Stock Ratings / Health Care / STAA / earnings

EYE (68) WRBY (52) BLCO (42) RXST (35) ⌘ Pro Terminal →

STAAR Surgical Company (STAA) Next Earnings Date & Expected ±8.5% Move

$25.24 +2.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

STAAR Surgical Company (STAA) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.27B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STAA)Realized 20D OHLCV Swing Band: ±8.5%

NEXT EST. WINDOW: Jan 1, 2027 (~60 DAYS)

Historical OHLCV Volatility ±8.5% Swing Band

±$2.15 Expected Swing

MODEL EARNINGS SETUP GAUGE

STAA Quantitative Pre-Earnings Setup: 38/100

Trailing EPS: $4.25 • YoY Revenue Growth: -23.7%

Model Bullish Setup (38/100)Model Risk Weight (62/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2026-01-02	$239.4M	-$80.4M	-$40.0M	76.2%
FY 2024	2024-12-27	$313.9M	-$20.2M	-$7.7M	76.3%
FY 2023	2023-12-29	$322.4M	$21.3M	$14.6M	76.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STAA)

✓Walkthrough of STAA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

STAA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.25%▲ RESISTANCE BREAKOUT

2026-10-30O $25.00H $25.42L $24.32C $25.24VOL 535.5K

RES: $20.88SUP: $17.69SMA50: $22.42SMA200: $23.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STAA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STAA Butterfly Map → + Track STAA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -23.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on STAA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STAA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for STAA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STAA)

Health Care Rank #700 of 1016 ⚔️ EYE vs STAA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STAA vs. EYE, WRBY, BLCO, RXST)

Industry: Ophthalmic Goods (8 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, STAAR Surgical Company (STAA) ranks #700 by composite RQD confidence (38/100, grade D-) and #329 by equity capitalization ($1.27B). Within this direct 5-issuer industry benchmark cohort, EYE leads on earnings valuation at 44.4x trailing P/E, while EYE leads on capital efficiency and profitability with 4.4% ROIC and — gross margin. EYE currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with STAA at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
STAA ACTIVE STAAR Surgical Company	D-	38/100	—	76.2%	-35.0%	+2.56%	$1.27B	Benchmark Subject
EYE National Vision Holdings Inc.	C+	68/100	44.4x	—	4.4%	+7.63%	$1.32B	/eye-vs-staa →
WRBY Warby Parker Inc.	D+	52/100	—	54.0%	-1.7%	+0.66%	$3.04B	/wrby-vs-staa →
BLCO Bausch + Lomb Corporation	D-	42/100	—	—	0.8%	0.00%	$7.29B	/blco-vs-staa →
RXST RxSight Inc.	D-	35/100	—	76.6%	-14.9%	+3.06%	$210.0M	/rxst-vs-staa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-01-02 • CIK 0000718937

In its most recent audited fiscal period (FY2025, filed 2026-01-02), STAAR Surgical Company (STAA) reported GAAP revenue of $239.4M (-23.7% vs. FY2024 revenue of $313.9M , and -25.7% cumulative change since FY2023) , GAAP net income of -$80.4M, operating cash flow of -$34.2M, and free cash flow of -$40.0M (-422.2% YoY). On the balance sheet, STAA closed FY2025 with $451.7M in total assets against $0 in total debt (Altman Z-Score: 7.11, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-01-02	$239.4M	-$80.4M	-$34.2M	-$40.0M	$451.7M	—
FY2024 (FY)	2024-12-27	$313.9M	-$20.2M	$15.7M	-$7.7M	$509.5M	—
FY2023 (FY)	2023-12-29	$322.4M	$21.3M	$14.6M	$14.6M	—	—

3. STAA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STAA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, STAAR Surgical Company (NASDAQ: STAA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $25.24 (+2.56% 1D, market cap $1.27B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STAA ranks #700 in composite RQD confidence.

How does STAA compare to EYE and WRBY in the Health Care sector?

Within the Health Care sector (Ophthalmic Goods), STAA carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 76.2%, and ROIC of -35.0%. By comparison, EYE (National Vision Holdings Inc.) holds a C+ grade (68/100 RQD, P/E 44.4x, ROIC 4.4%, cap $1.32B) and WRBY (Warby Parker Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -1.7%, cap $3.04B). Among the 5-stock peer group, EYE leads on earnings multiple (44.4x) while EYE leads on capital efficiency (4.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for STAA?

Per STAA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-02, CIK 0000718937), STAAR Surgical Company generated $239.4M in revenue (-23.7% YoY), -$80.4M in net income, and -$40.0M in free cash flow against $451.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is STAA trading relative to its 50-day, 200-day, and 52-week technical levels?

STAA last traded at $25.24 (+2.56% on volume of 454,652 shares), positioning the stock +12.58% above its 50-day simple moving average ($22.42) and +6.95% above its 200-day simple moving average ($23.60). Across its 52-week range of $15.59 to $35.87, STAA sits at the 47.6% percentile with a 14-day RSI of 61.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.5% ($23.09 to $27.39).